http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0127139-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6405b83c1ef3dde7f035f3368248684c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1601137c70c7c2a49943569b10c9044c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cc035d8fbbb9b142f50152e8e8204f81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4509e922a91a4f124d79e296c141ea9c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_82a97c44dbde78ba5df2b98056532a21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_65d887c9cfba89a488e69131c5bed757
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08
filingDate 2000-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_641b6374cbb2968a1fa75469f2ea9f1c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12047dffe5508244ef443bedd6b75fad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a79a77c9af7221d14bd8a5f2f16f618
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ade396c62cd49ec8d6cdf16238cb82b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b61bf840cfe5885d2c6381fc2cc44569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9d7cba4869421588ec38c26e432b7ad
publicationDate 2001-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-0127139-A1
titleOfInvention Drug for treatment of immunodeficiency states
abstract Use: the drug for treatment of immunodeficiency states is used in medicine, pharmacology, for treatment of the immunodeficiency states. Essence of the invention: the hexapeptide of the structural formula: lysil-histidil-glycil-lysil-histidil-glycine is offered as the drug for treatment. Additionally, the drug contains the stabiliser - glycine.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012129792-A1
priorityDate 1999-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4584284-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394566
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129152088
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226401477
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10707
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128039994
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406237
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID335
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15459053
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID342
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID81531
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394385
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10868
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID17986852
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393392
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393260
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7969
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394565

Total number of triples: 43.